Stent infringement

Boston Scientific Corporation today announced that a U.S. District Court jury in Marshall, Texas has reached a verdict in a patent infringement suit brought against the Company by Dr. Bruce Saffran. The jury found that the Company's TAXUS(R) and Liberte(TM) drug-eluting stent products infringe Dr. Saffran's patent and that the patent is valid. No injunction was requested, but the jury awarded damages of $431 million. The Company believes the jury verdict is unsupported by both the evidence and the law. On these grounds, the Company plans to seek to overturn the verdict in post-trial motions before the District Court and, if unsuccessful, to appeal to the U.S. Court of Appeals for the Federal Circuit. The Company believes it will prevail on appeal